Research Synthesis: NAD+ Metabolism Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Recode directional signals in the Findings Map to reflect what each cited source actually reports; separate biomarker-positive findings (NAD+ metabolite elevations across Katayoshi 2023, Conze 2019, Martens 2018, Elhassan 2019, Christen 2026, Holmes 2026) from clinical-endpoint findings (mixed/null on arterial stiffness, glucose/lipids, muscle function). The current coding collapses these distinct signal types into 'null' and misrepresents the evidence.
2. Reclassify Membrez 2024 as translational/mechanistic with human correlational component, and either reclassify or explicitly exclude Gao 2026 (mechanistic ARDS) and Qader 2025 (preclinical rodent review) from the clinical outcome-class tallies; update the evidence-role accounting that claims 'no mechanistic sources.'
3. Attribute every admitted source to at least one mapped outcome class or contextual role; Holmes 2026 (menopause/NRPT) currently appears in the bundle but is unaccounted for in the Findings Map.
4. Reconcile the '0 cross-study disagreements' claim with the actual divergence between NAD+-elevating biomarker studies and clinical-endpoint null studies (Connell 2021, Chen 2024); either clarify the disagreement-counting rule (biomarker vs. endpoint) or report the substantive tensions in the Tensions and Gaps section.
5. Expand Tensions and Gaps to cover the full outcome breadth of the corpus, including cognition (Yulug 2023, Qader 2025), menopause (Holmes 2026), and acute-care contexts (Gao 2026).
6. Verify the cited_as attributions against the source_bundle entries and confirm all 12 admitted sources are individually traceable to a finding row or contextual statement.

Major issues

• The Findings Map reports directional coding that directly contradicts the cited source bundle. Conze 2019 (NR safety/RCT) reports significant dose-dependent NAD+ increases (22%/51%/142%) and tolerability — coded as 'null' rather than positive. Martens 2018 (NR chronic supplementation RCT) reports effective NAD+ elevation and is 'well-tolerated' — coded null. Elhassan 2019 reports elevated muscle NAD+ metabolome and anti-inflammatory signatures — coded null. Katayoshi 2023 reports significant nicotinamide elevation and arterial stiffness trend reduction — coded null. Christen 2026 reports NR/NMN comparably increase circulatory NAD+ — coded null/unclear. The aggregate 'null signals cluster in cardiometabolic' framing misrepresents these primary sources, which predominantly show positive NAD+ biomarker signals with mixed/null clinical endpoint signals.
• Membrez 2024 (trigonelline, Nature Metabolism 2024) is miscoded as a primary clinical source for muscle function outcomes — it is primarily a mechanistic/translational paper spanning C. elegans, mice, and human correlational data, not a direct clinical trial; assigning it to 'muscle function' as 'directness: indirect' obscures its mechanistic character.
• Gao 2026 (SERPINE1/ARDS/ferroptosis) and Qader 2025 (preclinical rodent cognitive review) are mechanistically/model-system sources misclassified into clinical outcome classes; the manuscript claims 'no sources classified primarily as mechanistic or model-system evidence,' but the bundle contains both.
• Holmes 2026 is listed in source_bundle but never explicitly attributed to a finding row in the Findings Map table or outcome-class subsections.

Minor issues

• Search Summary uses future-dated queries and a 2026-06-19 retrieval window — verify this is not an artifact; if real, flag explicitly.
• Several bundle entries have year 2026 (Holmes 2026, Christen 2026, Gao 2026) and 2025 (Qader 2025) — DOI suffixes and PubMed IDs should be cross-checked for plausibility; Christen 2026 PMID 41540253 and Gao 2026 PMID 42190562 appear anomalously high for pre-2026 indexing.
• Evidence-tension synthesis section states '0 disagreement(s)' across the corpus while the Sources Map and abstract also state 0 disagreements — yet multiple sources reach divergent conclusions (e.g., Conze/Martens/Elhassan positive biomarker signals vs. Connell 2021 null on muscle function vs. Chen 2024 meta-analytic null on glucose/lipid); the '0 disagreements' count should be reconciled or the disagreement taxonomy clarified.
• The 'Contextual Adjacent Evidence' framing as a non-pooled category is reasonable, but its 5 sources are not individually enumerated in the Findings Map; readers cannot audit what those 5 sources are.
• Tensions and Gaps section directs future studies toward cardiometabolic, muscle function, safety comorbidity but does not address cognition, menopause, ARDS/ferroptosis, or trigonelline — the actual breadth of the admitted corpus.

Reviewer note

This evidence map attempts a tiered, source-attributed synthesis of NAD+ metabolism evidence and gets several structural elements right: explicit search summary, auditable admission funnel, named outcome classes, and an explicit refusal to collapse into a single causal or clinical claim. The limitations section honestly surfaces the lack of direct interventional hard-endpoint evidence. The gap section is specific and actionable. However, the central synthesis — the Findings Map's directional coding — materially misrepresents the cited sources. Multiple primary RCTs and mechanistic-translational studies in the bundle report positive NAD+ biomarker signals (Conze 2019 dose-dependent 22/51/142% NAD+ elevation; Martens 2018 chronic NAD+ elevation; Elhassan 2019 muscle NAD+ metabolome increase with anti-inflammatory signatures; Katayoshi 2023 significant nicotinamide elevation; Christen 2026 NR/NMN elevation of circulatory NAD+; Holmes 2026 NRPT for menopause symptoms). These are coded as 'null' or 'unclear,' and the abstract claims null signals cluster in cardiometabolic. Meanwhile, the genuine clinical-endpoint null findings (Connell 2021 on muscle function; Chen 2024 meta-analytic null on glucose/lipids) are not surfaced as the substantive tension they represent. The map also claims 'no mechanistic or model-system evidence' while Qader 2025 is a preclinical rodent review and Gao 2026 is a mechanistic ARDS/ferroptosis paper. The '0 cross-study disagreements' count is inconsistent with the actual divergence between biomarker-positive and endpoint-null findings unless a very narrow disagreement definition is being used, and that definition should be made explicit. These are not stylistic issues — they materially distort the evidence profile the map is supposed to faithfully represent. The manuscript is salvageable with bounded edits focused on recoding directional signals, reclassifying evidence roles, and surfacing the biomarker-vs-endpoint tension, but as submitted it overclaims a null profile that the cited sources do not jointly support. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis